Sionna Therapeutics, Inc. (SION) Price & Analysis

Compare

22 Followers

SION Stock Chart & Stats

$40.29

Market closed

$40.29

Day’s Range― - ―

52-Week Range$7.26 - $45.00

Previous CloseN/A

VolumeN/A

Average Volume (3M)246.04K

Market Cap

$1.80B

Enterprise Value$1.07B

Total Cash (Recent Filing)$248.33M

Total Debt (Recent Filing)$8.97M

Price to Earnings (P/E)―

Beta1.04

Next Earnings

Mar 19, 2026

EPS Estimate

-0.54

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.46

Shares Outstanding44,628,788

10 Day Avg. Volume294,354

30 Day Avg. Volume246,042

Financial Highlights & Ratios

PEG Ratio-0.59

Price to Book (P/B)-6.74

Price to Sales (P/S)0.00

P/FCF Ratio-20.89

Enterprise Value/Market Cap0.59

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-4.33K

Enterprise Value/Ebitda-14.19

Forecast

1Y Price Target

$42.75

Price Target Upside6.11% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering5

EPS Forecast (FY)-2

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentSionna Therapeutics is advancing novel cystic fibrosis drugs, with its co-founders developing two NBD1 stabilizers, SION-451 & SION-719, that are likely superior to the standard of care Trikafta.

Financial StabilitySION has $325 million in cash, providing operational funding through 2028, ensuring financial stability for future developments.

Market OpportunityThe cystic fibrosis drug market is substantial, and Sionna's innovative approach offers significant opportunities to improve the lives of patients who do not fully benefit from current treatments.

Bears Say

Drug PerformanceIf a drug has poor lung bioavailability or a patient's baseline disease is too advanced, it could perform less optimally in clinic than predicted by the assay.

Market PenetrationPatients stable on Trikafta are unlikely to be switched to a new drug, posing a challenge for market penetration.

Sionna Therapeutics, Inc. News

Midday Fly By: Nvidia invests in Synopsys, U.S. strikes pharma deal with UK

The major averages were broadly lower near noon, starting the month in the red as investors await fresh...

6d ago

Sionna downgraded to Underperform from Sector Perform at RBC Capital

RBC Capital downgraded Sionna Therapeutics (SION) to Underperform from Sector Perform with an unchanged price target of $24....

6d ago

SION

Sionna Therapeutics initiated with a Buy at BTIG

BTIG analyst Kambiz Yazdi initiated coverage of Sionna Therapeutics (SION) with a Buy rating and $50 price target...

18d ago

SION

BTIG Assigns Buy Rating to Sionna Therapeutics, Citing Innovative Cystic Fibrosis Therapies and Strong Market Potential

, an analyst from BTIG, has initiated a new Buy rating on Sionna Therapeutics, Inc. (SION). BTIG has...

18d ago

SION

Sionna Therapeutics: Promising Developments and Strategic Advancements Boost Price Target

JonesTrading analyst Debanjana Chatterjee has reiterated their bullish stance on SION stock, giving a Buy rating on November...

20d ago

SION

Sionna Therapeutics Advances CF Pipeline Amid Strong Financials

Sionna Therapeutics, Inc. ( ($SION) ) has released its Q3 earnings. Here is a breakdown of the information...

30d ago

SION

Sionna Therapeutics reports Q3 EPS (46c), consensus (47c)

“We maintain our track record of strong execution, achieving substantial progress across our pipeline in the third quarter....

1M ago

SION

Sionna Therapeutics expects cash to fund operations into 2028

Maintained strong cash position with approximately $325.0 million in cash and cash equivalents, expected to fund operations into...

1M ago

SION

Sionna Therapeutics Advances Cystic Fibrosis Treatment with New Study

Sionna Therapeutics, Inc. (($SION)) announced an update on their ongoing clinical study. Sionna Therapeutics, Inc. is conducting a...

1M ago

SION

Sionna Therapeutics Advances Phase 1 Study for Cystic Fibrosis Treatment

Sionna Therapeutics, Inc. (($SION)) announced an update on their ongoing clinical study. Sionna Therapeutics, Inc. (SION) is currently...

1M ago

SION

Sionna Therapeutics announces initiation of PreciSION CF Phase 2a trial

Sionna Therapeutics (SION) announced initiation of the PreciSION CF Phase 2a proof-of-concept trial evaluating SION-719, a first-in-class nucleotide...

2M ago

SION

Sionna Therapeutics initiated with a Buy at Freedom Capital

Freedom Capital initiated coverage of Sionna Therapeutics (SION) with a Buy rating and $38 price target Completed Phase...

2M ago

SION

Sionna Therapeutics appoints Caroline Stark Beer as CBO

Sionna Therapeutics (SION) announced the appointment of Caroline Stark Beer, MBA, as its Chief Business Officer. She was...

3M ago

SION

Sionna Therapeutics initiated with a Buy at JonesResearch

JonesResearch initiated coverage of Sionna Therapeutics (SION) with a Buy rating and $46 price target Sionna is clinical...

3M ago

SION

SION FAQ

What was Sionna Therapeutics, Inc.’s price range in the past 12 months?

Sionna Therapeutics, Inc. lowest stock price was $7.25 and its highest was $45.00 in the past 12 months.

What is Sionna Therapeutics, Inc.’s market cap?

Sionna Therapeutics, Inc.’s market cap is $1.80B.

When is Sionna Therapeutics, Inc.’s upcoming earnings report date?

Sionna Therapeutics, Inc.’s upcoming earnings report date is Mar 19, 2026 which is in 102 days.

How were Sionna Therapeutics, Inc.’s earnings last quarter?

Sionna Therapeutics, Inc. released its earnings results on Nov 05, 2025. The company reported -$0.46 earnings per share for the quarter, beating the consensus estimate of -$0.484 by $0.024.

Is Sionna Therapeutics, Inc. overvalued?

According to Wall Street analysts Sionna Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sionna Therapeutics, Inc. pay dividends?

Sionna Therapeutics, Inc. does not currently pay dividends.

What is Sionna Therapeutics, Inc.’s EPS estimate?

Sionna Therapeutics, Inc.’s EPS estimate is -0.54.

How many shares outstanding does Sionna Therapeutics, Inc. have?

Sionna Therapeutics, Inc. has 44,628,788 shares outstanding.

What happened to Sionna Therapeutics, Inc.’s price movement after its last earnings report?

Sionna Therapeutics, Inc. reported an EPS of -$0.46 in its last earnings report, beating expectations of -$0.484. Following the earnings report the stock price went down -1.571%.

Which hedge fund is a major shareholder of Sionna Therapeutics, Inc.?

Currently, no hedge funds are holding shares in SION

Sionna Therapeutics, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-28.07%

Trailing 12-Months

Asset Growth

71.99%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sionna Therapeutics, Inc.

Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.

Sionna Therapeutics, Inc. (SION) Earnings & Revenues

Historic Earnings Reports

SION Stock 12 Month Forecast

Average Price Target

$42.75

▲(6.11% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"$9","20":"$20","31":"$31","42":"$42","53":"$53"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":52,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$52.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$42.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$24.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,20,31,42,53],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"Apr<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.96,39.963076923076926,40.966153846153844,41.96923076923077,42.972307692307695,43.97538461538461,44.97846153846154,45.98153846153846,46.98461538461538,47.987692307692306,48.99076923076923,49.99384615384615,50.996923076923075,{"y":52,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.96,39.25153846153846,39.543076923076924,39.83461538461538,40.12615384615385,40.417692307692306,40.70923076923077,41.00076923076923,41.292307692307695,41.58384615384615,41.87538461538462,42.16692307692308,42.458461538461535,{"y":42.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,38.96,37.80923076923077,36.65846153846154,35.50769230769231,34.35692307692308,33.206153846153846,32.05538461538462,30.904615384615386,29.753846153846155,28.603076923076923,27.45230769230769,26.301538461538463,25.15076923076923,{"y":24,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.24,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.24,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.24,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.24,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.77,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.77,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.16,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.92,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.39,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.47,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.21,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.96,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >